Press release - 17/01/2024 Immatics Announces Pricing of $175 Million Public Offering Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced today the pricing of an underwritten public offering of 15,925,000 ordinary shares at a public offering price of $11.00 per share. https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-announces-pricing-175-dollar-million-public-offering
Press release - 05/01/2024 Prostate cancer: Newly-developed inhibitor shows massive potential More than 65,000 men fall ill with prostate cancer each year in Germany. Twelve thousand of them develop a treatment-resistant form which eventually ends in death. Now, a team of researchers from the Medical Faculty at the University of Freiburg has developed an active substance that might in future represent a new treatment option. https://www.gesundheitsindustrie-bw.de/en/article/press-release/prostate-cancer-newly-developed-inhibitor-shows-massive-potential
Press release - 04/01/2024 Key player in viral heart inflammation discovered Inflammation of the heart muscle, also known as myocarditis, is a serious consequence of a viral infection. This can impede the heart’s ability to pump blood in the long term. In a current study, researchers of the Faculty of Medicine of the University of Freiburg have discovered a new approach for treating myocarditis. https://www.gesundheitsindustrie-bw.de/en/article/press-release/key-player-viral-heart-inflammation-discovered
Press release - 15/01/2024 Maturation instead of cell death: Defective signalling pathways disrupt immune cell development Researchers at the Faculty of Medicine of the University of Freiburg discover key factor in the development of immune cells. New approaches for the treatment of ALPS.https://www.gesundheitsindustrie-bw.de/en/article/maturation-instead-cell-death-defective-signalling-pathways-disrupt-immune-cell-development
Event - 18/09/2024 - 20/09/2024 58th Annual Conference of the German Society for Biomedical Engineering (BMT 2024) Stuttgart, Kongress/Symposium https://www.gesundheitsindustrie-bw.de/en/event/58th-annual-conference-german-society-biomedical-engineering-bmt-2024
Press release - 02/02/2024 University of Stuttgart successful with cluster draft proposals The German Research Foundation (DFG) has announced the first pivotal decisions for the "Clusters of Excellence" funding line as part of the Excellence Strategy of the German federal and state governments. The University of Stuttgart has been given the green light for two new cluster initiatives. https://www.gesundheitsindustrie-bw.de/en/article/press-release/universitaet-stuttgart-mit-clusterskizzen-erfolgreich
Press release - 06/02/2024 New T-FINDER Platform Provides Deep Insights Into T Cell Responses Against Novel Cancer Vaccine BioMed X and the Universitätsmedizin Mannheim announced today the publication of two manuscripts in the field of cancer immunology in the journal Science Advances. The work is based on a collaboration bet- ween both institutions and researchers at the German Cancer Research Center (DKFZ), the Heidelberg Uni- versity, and the Helmholtz Institute for Translational Oncology (HI-TRON).https://www.gesundheitsindustrie-bw.de/en/article/press-release/neue-t-finder-plattform-liefert-tiefe-einblicke-t-zell-antwort-auf-neuartigen-krebsimpfstoff
Press release - 10/01/2024 MedTech Company KARL STORZ Acquires British AI Specialist Innersight Labs The family-owned MedTech company KARL STORZ announces the acquisition of the innovative software manufacturer Innersight Labs Ltd. (ISL) headquartered in London. In addition to state-of-the-art endoscopes, high-end medical devices, and integrated solutions for the operating room, KARL STORZ is also continuing to expand in innovative software solutions. https://www.gesundheitsindustrie-bw.de/en/article/press-release/medtech-company-karl-storz-acquires-british-ai-specialist-innersight-labs
Press release - 02/02/2024 Epigenetic status determines metastasis Scientists from the German Cancer Research Center (DKFZ) and Medical Faculty Mannheim of the Heidelberg University investigated in mice how spreading tumor cells behave at the site of metastasis: Some tumor cells immediately start to form metastases. Others leave the blood vessel and may then enter a long period of dormancy. What determines which path the cancer cells take is their epigenetic status. https://www.gesundheitsindustrie-bw.de/en/article/press-release/epigenetischer-status-entscheidet-ueber-metastasierung
Press release - 31/01/2024 Precursor of Cholesterol Protects Cancer Cells From Cell Death and Makes them Aggressive A precursor of cholesterol can protect cancer cells from a form of cell death known as ferroptosis. Scientists of the University of Würzburg, the German Cancer Research Center (DKFZ), and the Stem Cell Institute HI-STEM* published this finding in the journal Nature. The results opens up exciting prospects for further improving the treatment of cancer and other diseases associated with oxidative stress and ferroptosis.https://www.gesundheitsindustrie-bw.de/en/article/press-release/cholesterin-vorstufe-schuetzt-krebszellen-vor-zelltod-und-macht-sie-aggressiver
Press release - 18/01/2024 Indicator for liver health status identified A high-fat, high-sugar diet damages the liver in the long term. Scientists at the German Cancer Research Center (DKFZ) have now identified a characteristic change in the molecular signaling pathways of liver cells in mice that were exposed to such a diet for weeks. It fuels the division activity of hepatocytes and correlates with the risk of patients suffering liver failure after liver surgery.https://www.gesundheitsindustrie-bw.de/en/article/press-release/indicator-liver-health-status-identified
Press release - 17/01/2024 AI-based support system for skin cancer diagnostics explains its decisions Artificial intelligence (AI) can help dermatologists to detect skin cancer. However, many dermatologists distrust the algorithms' decisions, which they cannot comprehend. Scientists at the German Cancer Research Center have now developed an AI-based support system for skin cancer diagnostics that explains its decisions.https://www.gesundheitsindustrie-bw.de/en/article/press-release/ai-based-support-system-skin-cancer-diagnostics-explains-its-decisions
Neurosciences - 28/02/2024 Mesh microelectrode arrays: research with brain organoids on a new level How does the brain work? Brain organoids are derived from pluripotent stem cells and regarded as valuable model systems that can depict some aspects of neurological functioning. Dr. Peter Jones from NMI together with Dr. Thomas Rauen from the MPI for Molecular Biomedicine in Münster, has taken organoid research to a new level. His novel mesh microelectrode array (Mesh-MEA) greatly improves the growth and electrophysiological analysis of tissue.https://www.gesundheitsindustrie-bw.de/en/article/news/mesh-microelectrode-arrays-research-brain-organoids-new-level
Event - 22/10/2024 2nd Biointelligence Congress in Stuttgart Stuttgart (Germany), Kongress/Symposium https://www.gesundheitsindustrie-bw.de/en/event/2nd-biointelligence-congress-stuttgart
Press release - 12/02/2024 AI-supported image analysis: metrics determine quality How well do the algorithms used in the AI-supported analysis of medical images perform their tasks? This depends to a large extent on the metrics used to evaluate their performance. An international consortium led by scientists from the German Cancer Research Center and the National Center for Tumor Diseases has compiled the knowledge available worldwide on the specific strengths, weaknesses and limitations of the various validation metrics.https://www.gesundheitsindustrie-bw.de/en/article/news/ai-supported-image-analysis-metrics-determine-quality
Press release - 07/02/2024 The unexpected long-term consequences of female fertility The constant remodeling of the organs of the female reproductive tract during the reproductive cycle leads to fibrosis and chronic inflammation over the years. Scientists from the German Cancer Research Center (DKFZ) have now uncovered these unexpected long-term consequences of female reproductive function in mice. The results have been published in the scientific journal CELL.https://www.gesundheitsindustrie-bw.de/en/article/press-release/die-unerwartete-auswirkung-der-weiblichen-fortpflanzungsfaehigkeit
Press release - 15/02/2024 Modelling the spread of diseases Computer scientists from the Cluster of Excellence Collective Behaviour developed a model, that explains how collective scenarios such as diseases may proceed.https://www.gesundheitsindustrie-bw.de/en/article/press-release/modelling-spread-diseases
Funding Future Insight Prize Funding programme, Funded by: Merck KGaA, sb_search.searchresult.label.programSubmissionDate: 31/12/2022 https://www.gesundheitsindustrie-bw.de/en/database/funding/future-insight-prize
Funding Erasmus for Young Entrepreneurs Scholarship, Funded by: EUhttps://www.gesundheitsindustrie-bw.de/en/database/funding/erasmus-for-young-entrepreneurs
Event - 18/09/2024 - 20/09/2024 GCSB 2024 German Conference on Synthetic Biology 2024 Regensburg, Kongress/Symposium https://www.gesundheitsindustrie-bw.de/en/event/gcsb-2024-german-conference-synthetic-biology-2024
Event - 10/07/2024 - 11/07/2024 Curious2024 – Future Insight™ Conference Mainz, Kongress/Symposium https://www.gesundheitsindustrie-bw.de/en/event/curious-2024-future-insight-conference
Dossier - 10/09/2012 Horizon 2020 the EU framework programme for research and innovation a boost for top-level research in Europe In the face of the ongoing financial crisis Europe is working on a new research strategy that is aimed at creating new economic growth and jobs. The new EU framework programme for research and innovation Horizon 2020 replaces the 7th Framework Programme FP7 and will run from 2014 with a budget of 80 billion. In July 2012 Brussels launched the final FP7 calls for proposals for 2013 that offer numerous market-based instruments designed to bridge…https://www.gesundheitsindustrie-bw.de/en/article/dossier/horizon-2020-the-eu-framework-programme-for-research-and-innovation-a-boost-for-top-level-research-i
Article - 10/01/2019 Stocktaking and recommendations for action: the BBAW’s fourth gene technology report In the new gene technology report, the interdisciplinary working group of the Berlin-Brandenburg Academy of Sciences (BBAW) takes stock of gene technology developments in Germany during the past few decades, and discusses the societal, legal and ethical challenges associated with these technologies in the future. The report is highly topical due to the controversy surrounding the ruling of the European Court of Justice on CRISPR/Cas9 genome…https://www.gesundheitsindustrie-bw.de/en/article/news/stocktaking-and-recommendations-for-action-the-bbaws-fourth-gene-technology-report
Article - 19/09/2019 Magnetised algae as microrobots for medical and environmental purposes Algae, for most of us, is something that lives in water courses that we occasionally find unpleasant. However, that is to do them a wrong. These extremely versatile and frugal organisms might in future prove to be extremely important. Scientists at the University of Stuttgart are investigating how algae can be used as microrobots in biomedicine and environmental remediation.https://www.gesundheitsindustrie-bw.de/en/article/news/magnetisierte-algen-als-mikroroboter-fuer-medizin-und-umwelt
Funding Digital Europe Programme Funding programme, Funded by: European Commission, sb_search.searchresult.label.programSubmissionDate: 31/12/2027 https://www.gesundheitsindustrie-bw.de/en/database/funding/digital-europe-programme
Funding EU4Health- Programme Funding programme, Funded by: European Union, sb_search.searchresult.label.programSubmissionDate: 31/12/2027 https://www.gesundheitsindustrie-bw.de/en/database/funding/eu4health-programme
Funding Horizone Europe Funding programme, Funded by: European Union, sb_search.searchresult.label.programSubmissionDate: 31/12/2027 https://www.gesundheitsindustrie-bw.de/en/database/funding/horizone-europe
Funding Novartis announces broad range of initiatives to respond to COVID-19 Pandemic Funding programme, Funded by: Novartis AGhttps://www.gesundheitsindustrie-bw.de/en/database/funding/novartis-announces-broad-range-initiatives-respond-covid-19-pandemic
Funding Venture Center of Excellence Funding programme, Funded by: EIT Health e.V. und European Investment Fund (EIF), sb_search.searchresult.label.programSubmissionDate: 31/12/2022 https://www.gesundheitsindustrie-bw.de/en/database/funding/venture-center-excellence
Dossier - 12/10/2022 The health sector must become greener Worldwide, the health sector is struggling with the consequences of global warming, but fatally is itself responsible for a significant proportion of greenhouse gas emissions. Studies show that hospitals and rehabilitation clinics in particular have great potential for reducing these emissions and, like the manufacturing industry, need to fundamentally revise established processes.https://www.gesundheitsindustrie-bw.de/en/article/dossier/health-sector-must-become-greener
Climate protection and sustainability in hospitals - 09/11/2022 Sustainable activities in the healthcare sector The healthcare sector is not only facing major challenges in dealing with the consequences of climate change on human health, but it also needs to make a concrete contribution to reducing its own greenhouse gas emissions. Analyses show there are many opportunities to make medical care more sustainable, especially in hospitals’ daily routines. This is where the Heidelberg University Hospital and the viamedica foundation from Freiburg come in.https://www.gesundheitsindustrie-bw.de/en/article/news/sustainable-activities-healthcare-sector
Climate protection and sustainability in hospitals - 09/11/2022 Sustainable activities in the healthcare sector The healthcare sector is not only facing major challenges in dealing with the consequences of climate change on human health, but it also needs to make a concrete contribution to reducing its own greenhouse gas emissions. Analyses show there are many opportunities to make medical care more sustainable, especially in hospitals’ daily routines. This is where the Heidelberg University Hospital and the viamedica foundation from Freiburg come in.https://www.gesundheitsindustrie-bw.de/en/article/news/sustainable-activities-healthcare-sector
Climate protection and sustainability in hospitals - 09/11/2022 Sustainable activities in the healthcare sector The healthcare sector is not only facing major challenges in dealing with the consequences of climate change on human health, but it also needs to make a concrete contribution to reducing its own greenhouse gas emissions. Analyses show there are many opportunities to make medical care more sustainable, especially in hospitals’ daily routines. This is where the Heidelberg University Hospital and the viamedica foundation from Freiburg come in.https://www.gesundheitsindustrie-bw.de/en/article/news/sustainable-activities-healthcare-sector
Funding 4C Accelerator Tübingen Funding programme, Funded by: Medical Innovations Incubator GmbH, Ministerium für Wirtschaft, Arbeit und Tourismus BW, Startup BW & B. Braun-Stiftung, sb_search.searchresult.label.programSubmissionDate: 20/01/2023 https://www.gesundheitsindustrie-bw.de/en/database/funding/4c-accelerator-tuebingen
Press release - 07/08/2023 Vegan trend in Europe: In Germany, milk substitutes from plants are most popular alternative Germany has the most active market, Southern Europe wants more variety, and people in Poland find dairy substitutes too expensive, according to a recent study by the University of Hohenheim.https://www.gesundheitsindustrie-bw.de/en/article/press-release/vegan-trend-europe-germany-milk-substitutes-plants-are-most-popular-alternative
Press release - 29/11/2022 Prototype funding for two Konstanz projects Chemical building blocks from plastic waste; Reducing the risk of falls using virtual orientation aids: Konstanz chemists Manuel Häußler and Lukas Odenwald as well as sport scientist Lorenz Assländer receive Baden-Württemberg prototype funding for their transfer projects "Waste2DCA" and "Augmented Balance".https://www.gesundheitsindustrie-bw.de/en/article/press-release/doppelter-erfolg-der-prototypenfoerderung
Funding EU4Health Programme (EU4H) – Action Grants 2022 Funding programme, Funded by: European Union, sb_search.searchresult.label.programSubmissionDate: 21/02/2023 https://www.gesundheitsindustrie-bw.de/en/database/funding/eu4health-programme-eu4h-action-grants-2022
Press release - 22/02/2024 A new approach to recording cellular activities In living cells, a vast number of transient events occur simultaneously. The recording of these activities is a prerequisite for a molecular understanding of life. Scientists at the MPI for Medical Research in Heidelberg and their collaboration partners have created a novel technology that allows cellular events to be recorded through chemical labeling with fluorescent dyes for later analysis, opening up new ways to study cellular physiology.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-approach-recording-cellular-activities
Press release - 04/03/2024 Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million HealthCare Royalty to purchase royalties from worldwide sales of Telix Pharmaceuticals’ imaging diagnostic agent ZircaixTM (TLX250-CDx) Heidelberg Pharma is eligible to receive up to USD 115 million in three near-term tranches Cumulative royalties sold are capped at a maximum valuehttps://www.gesundheitsindustrie-bw.de/en/article/press-release/heidelberg-pharma-announces-royalty-financing-agreement-healthcare-royalty-usd-115-million
Press release - 05/03/2024 New Center for Synthetic Genomics Applying and developing new technologies for DNA synthesis to pave the way for producing entire artificial genomes – that is the goal of a new interdisciplinary center, 'Center for Synthetic Genomics', that is being established at Heidelberg University, Karlsruhe Institute of Technology (KIT), and Johannes Gutenberg University Mainz (JGU). https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-center-synthetic-genomics
Press release - 04/03/2024 First Step Toward Early Diagnosis of Metastasis Team involving the University of Freiburg has developed a new analytical method for the basement membrane in human lungs.https://www.gesundheitsindustrie-bw.de/en/article/press-release/first-step-toward-early-diagnosis-metastasis
Press release - 01/03/2024 Using Data to Improve Understanding of Relationships between Proteins and Diseases Working with a new Emmy Noether Group, Dr. Pascal Schlosser is investigating how machine learning can aid in understanding the complex relationships between genes, proteins, and diseases.https://www.gesundheitsindustrie-bw.de/en/article/press-release/using-data-improve-understanding-relationships-between-proteins-and-diseases
Stem cell research - 14/03/2024 Using organoids to gain a better clinical understanding of pancreatic cancer Prof. Dr. Alexander Kleger carries out translational research at Ulm University Hospital to gain a better understanding of pancreatic ductal adenocarcinoma (PDAC) and develop individualised treatments. He and his team are using organoid models and stem cell-based systems and have succeeded in simultaneously cultivating all three main cell types of the pancreas from pluripotent stem cells.https://www.gesundheitsindustrie-bw.de/en/article/news/using-organoids-gain-better-clinical-understanding-pancreatic-cancer
Press release - 14/03/2024 Next milestone in the treatment of liver tumors and acute and chronic liver diseases The results of a Tuebingen-led study raise hope that a newly developed drug could herald a new era in oncological liver surgery and transplantation. The drug could even have the potential to significantly improve the treatment of acute and chronic liver diseases. The drug candidate "HRX-215" is a so-called MKK4 inhibitor, i.e. the drug inhibits the MKK4 protein found in liver cells and thus leads to an increase in the regeneration of…https://www.gesundheitsindustrie-bw.de/en/article/press-release/next-milestone-treatment-liver-tumors-and-acute-and-chronic-liver-diseases
Epifadin from the nasal microbiome - 28/03/2024 From the nose: novel antibiotic substance discovered Antibiotics are becoming an increasingly blunt weapon against infectious diseases. The number of (multi-)resistant germs has been rising rapidly for years and even reserve antibiotics no longer work. Researchers at the University of Tübingen have now isolated a completely new antibiotic substance called epifadin from the microbiome of the human nose. It is effective against many different bacteria - including the dangerous hospital MRSA.https://www.gesundheitsindustrie-bw.de/en/article/news/nose-novel-antibiotic-substance-discovered
Press release - 13/03/2024 Diabetes: New technology opens up improved opportunities for research More than seven million people in Germany suffer from diabetes. At the same time, research into drugs to treat this widespread disease is still difficult. Scientists led by Prof. Dr. Peter Loskill from the NMI Natural and Medical Sciences Institute and the Faculty of Medicine of the Eberhard Karls University of Tübingen have now developed a technique that significantly improves the view at the molecular and cell biological level in the pancreas.https://www.gesundheitsindustrie-bw.de/en/article/press-release/diabetes-new-technology-opens-improved-opportunities-research
Press release - 14/03/2024 Planned NMI spin-off: immuneAdvice successful in start-up competition Does our therapeutic approach work against cancer? The answer to this question can make the difference between life and death - and is still difficult to answer. A team from the NMI Natural and Medical Sciences Institute at the University of Tübingen and the Werner Siemens Imaging Center Tübingen has developed a technique for observing immune cells. https://www.gesundheitsindustrie-bw.de/en/article/press-release/geplante-nmi-ausgruendung-immuneadvice-bei-startup-wettbewerb-erfolgreich
Press release - 22/03/2024 Decoding the shared genetic toolkit for male sex determination Researchers from the Max Planck Institute for Biology Tübingen broke new ground by demonstrating that an HMG-box gene in brown algae is crucial for determining male sex. This breakthrough significantly expands our understanding of sex-determination mechanisms in eukaryotic organisms. Until now, master sex-determination genes had been identified in only a select number of animals and plants. https://www.gesundheitsindustrie-bw.de/en/article/press-release/decoding-shared-genetic-toolkit-male-sex-determination
Press release - 14/03/2024 Machine learning classifier accelerates the development of cellular immunotherapies Making a personalised T cell therapy for cancer patients currently takes at least six months; scientists at the German Cancer Research Center (DKFZ) and the University Medical Center Mannheim have shown that the laborious first step of identifying tumor-reactive T cell receptors for patients can be replaced with a machine learning classifier that halves this time.https://www.gesundheitsindustrie-bw.de/en/article/press-release/machine-learning-classifier-accelerates-development-cellular-immunotherapies
Press release - 13/03/2024 Protection from an unexpected source Contrary to common belief, not all viruses are harmful to their hosts. Sometimes viruses can even protect their hosts from infection by other viruses. Scientists at the Max-Planck-Institute for Medical Research in Heidelberg and their collaborators have now demonstrated that this is the case for so-called endogenous virophages: small DNA viruses that are mostly found inserted into the genomes of single-cell eukaryotes.https://www.gesundheitsindustrie-bw.de/en/article/press-release/protection-unexpected-source
Press release - 22/03/2024 New Emmy Noether junior research group for biological data science An Emmy Noether junior research group at Heidelberg University is investigating how to gain new insights into fundamental biological mechanisms from large-scale molecular data sets. Led by Junior Professor Dr Britta Velten, it has started work at the Centre for Organismal Studies and the Interdisciplinary Center for Scientific Computing. https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-emmy-noether-junior-research-group-biological-data-science
Press release - 27/03/2024 Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101 Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for the treatment of multiple myeloma to its lead candidate HDP-101. Heidelberg Pharma is investigating the candidate in a clinical Phase I/IIa study for the treatment of relapsed/refractory multiple myeloma (RRMM).https://www.gesundheitsindustrie-bw.de/en/article/press-release/heidelberg-pharma-granted-orphan-drug-designation-fda-its-proprietary-atac-candidate-hdp-101
Press release - 02/04/2024 Precise localization of miniature robots and surgical instruments inside the body In the medicine of the future, tiny robots will navigate independently through tissue and medical instruments will indicate their position inside the body during surgery. Both require doctors to be able to localize and control the devices precisely and in real time. Scientists from the German Cancer Research Center (DKFZ) have now described a signaling method based on an oscillating magnet that can significantly improve such medical applications.https://www.gesundheitsindustrie-bw.de/en/article/press-release/precise-localization-miniature-robots-and-surgical-instruments-inside-body
Event - 18/06/2024 - 20/06/2024 MedtecLIVE 2024 Stuttgart, Messe https://www.gesundheitsindustrie-bw.de/en/event/medteclive-2024
Press release - 10/04/2024 Cyber Valley grants 500K to CELL’n’ROLL via 2023 Innovation Fellowship Program Pioneering cutting-edge diagnostic systems for the detection of complex diseases: Cyber Valley is pleased to announce it has awarded funding of 500K EUR to the CELL’n’ROLL team through the 2023 Cyber Valley Innovation Fellowship program, funded by the Carl-Zeiss-Stiftung.https://www.gesundheitsindustrie-bw.de/en/article/press-release/cyber-valley-grants-500k-cellnroll-2023-innovation-fellowship-program
Event - 22/05/2024 - 24/05/2024 The MedTech Forum 2024 Vienna, Austria, Conference https://www.gesundheitsindustrie-bw.de/en/event/medtech-forum-2024
Press release - 10/04/2024 Growth through medical technology: Bosch and Randox invest heavily in the Vivalytic analysis platform With its Vivalytic analysis platform, Bosch has set itself the goal of making fast and highly precise diagnostics accessible at the point of care – and aims to use molecular diagnostics to become a leading provider in the market by 2030. To achieve this, Bosch has now agreed on a strategic partnership with Randox Laboratories Ltd., a leading diagnostic and medical technology company.https://www.gesundheitsindustrie-bw.de/en/article/press-release/growth-through-medical-technology-bosch-and-randox-invest-heavily-vivalytic-analysis-platform
Press release - 18/04/2024 Additional partnership in medical technology: Bosch and R-Biopharm to strengthen Vivalytic analysis platform The market for medical technology is innovative, dynamic, and growing. Bosch sees medical technology as a strategic growth field and intends to expand its Bosch Healthcare Solutions subsidiary, based in Waiblingen. Bosch has now entered into a new partnership with the German diagnostics solutions company R-Biopharm. This partnership will be focused on Bosch’s universal, fully automated Vivalytic molecular diagnostic analysis platform. https://www.gesundheitsindustrie-bw.de/en/article/press-release/additional-partnership-medical-technology-bosch-and-r-biopharm-strengthen-vivalytic-analysis-platform
Press release - 18/04/2024 Collagen: Researchers at the NMI decipher how it works in medical treatment Collagen has been used in ophthalmology since the 1990s, particularly in the treatment of corneal defects. However, why and how this technique works was only known in theory. Researchers at the NMI Natural and Medical Sciences Institute in Reutlingen led by Lu Fan have found the necessary evidence and can now reliably explain how this technique works.https://www.gesundheitsindustrie-bw.de/en/article/press-release/collagen-researchers-nmi-decipher-how-it-works-medical-treatment
Press release - 11/04/2024 How the body switches out of “fight” mode Study in Nature unlocks how cortisone inhibits inflammation Cortisone and other related glucocorticoids are extremely effective at curbing excessive immune reactions. But previously, astonishingly little was known about how they exactly do that. A team of researchers from Charité – Universitätsmedizin Berlin, Uniklinikum Erlangen and Ulm University have now explored the molecular mechanism of action in greater detail. https://www.gesundheitsindustrie-bw.de/en/article/press-release/wie-der-kampfmodus-im-koerper-beendet-wird-studie-nature-entschluesselt-wie-kortison-entzuendungen-daempft
Press release - 17/04/2024 Cell Biology: Molecular Code Stimulates Pioneer Cells to Build Blood Vessels in the Body Cardiovascular diseases, including stroke and myocardial infarction, are the world's leading causes of mortality, accounting for over 18 million deaths a year. A team of KIT researchers has now identified a new cell type in blood vessels responsible for vascular growth. This discovery may allow for novel therapeutic strategies to treat ischemic cardiovascular diseases, i.e. diseases that are caused by reduced or absent blood flow.https://www.gesundheitsindustrie-bw.de/en/article/press-release/zellbiologie-molekularer-code-regt-pionierzellen-zum-aufbau-von-blutgefaessen-im-koerper
Press release - 19/04/2024 Electrified bacteria PhD student at Furtwangen University develops method for faster determination of antibiotic resistance. The increase in antibiotic-resistant pathogens and the associated treatment, which is a major problem in public healthcare facilities, is the subject of a research project at Furtwangen University.https://www.gesundheitsindustrie-bw.de/en/article/press-release/bakterien-unter-strom
Event - 16/10/2024 - 17/10/2024 Diagnostics-4-Future Conference 2024 Konstanz, Germany, Conference https://www.gesundheitsindustrie-bw.de/en/event/diagnostics-4-future-conference-2024
Press release - 25/04/2024 Diamond dust shines bright in Magnetic Resonance Imaging An unexpected discovery surprised a scientist at the Max Planck Institute for Intelligent Systems in Stuttgart: nanometer-sized diamond particles, which were intended for a completely different purpose, shone brightly in a magnetic resonance imaging experiment – much brighter than the actual contrast agent, the heavy metal gadolinium. Could diamond dust one day become a novel contrast agent used for MRI? https://www.gesundheitsindustrie-bw.de/en/article/press-release/diamond-dust-shines-bright-magnetic-resonance-imaging
Press release - 24/04/2024 CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK Phase 1 part of combined Phase 1/2 study initiated as part of pandemic preparedness against highly pathogenic avian influenza (H5N1) virus, considered to be potential future pandemic threat. Study will assess monovalent vaccine candidate, encoding an influenza A H5-antigen using proprietary second-generation mRNA backbone. https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-announces-start-combined-phase-12-study-avian-influenza-h5n1-development-collaboration-gsk
Press release - 03/05/2024 Newly discovered mechanism of T-cell control can interfere with cancer immunotherapies Activated T cells that carry a certain marker protein on their surface are controlled by natural killer cells. In this way, the body presumably curbs destructive immune reactions. Researchers now discovered that NK cells can impair the effect of cancer therapies with immune checkpoint inhibitors in this way. They could also be responsible for the rapid decline of therapeutic CAR-T cells. https://www.gesundheitsindustrie-bw.de/en/article/press-release/newly-discovered-mechanism-t-cell-control-can-interfere-cancer-immunotherapies